OPKO Health (OPK) Q4 Earnings Decline Y/Y, Margins Down

OPKO Health, Inc.OPK reported loss of 38 cents per share in the fourth quarter of 2017 compared with loss of 4 cents a year ago. The Zacks Consensus Estimate for the quarter was pegged at a loss of 8 cents.

The company reported full-year 2017 loss of 55 cents, comparing unfavorably with the year-ago loss of 5 cents .


In the fourth quarter, OPKO Health generated total revenues of $193.7 million, down 29.7% year over year from $275.5 million. The reported figure also missed the Zacks Consensus Estimate of $307 million.

Net revenues in 2017 totaled $1.07 billion, down 12.3% from the year-ago number of $1.22 billion.

Gross profit in the fourth quarter was $37.1 million, down 68.1% year over year. Gross margin contracted a massive 2300 basis points (bps) to 19.2% from 42.1% in the year-ago quarter.

Opko Health, Inc. Price, Consensus and EPS Surprise

Opko Health, Inc. Price, Consensus and EPS Surprise | Opko Health, Inc. Quote

Research and development expenses totaled $34.2 million, up 23.9% year over year while selling, general and administrative expenses amounted to $124.6 million, up 3.4%. Consequently, loss from operations came in at $121.7 million, highlighting a significant decline from an operating loss of $31.9 million in the prior-year quarter. The decline can be attributed to a rise in operating expenses owing to the company's significant investments associated with the commercial launch of RAYALDEE along with consistent investments in the pharmaceutical pipeline.


OPKO Health exited 2017 with cash and cash equivalents and marketable securities of $91.5 million compared with $168.7 million recorded at the end of 2016.

Our Take

OPKO Health exited the fourth quarter on a disappointing note.

Nonetheless, we are encouraged by the ongoing developments in all of the company's businesses, which include diagnostics business as Bio-Reference Laboratories and pharmaceutical business. We are also upbeat about OPKO Health's growing revenues from GeneDx, Bio-Reference's genetic testing unit and the 4Kscore test in the quarter.

However, the rise in operating expenses might continue to mar the company's financials.

Zacks Rank & Key Picks

OPKO Health has a Zacks Rank #3 (Hold).

A few better-ranked stocks that reported solid results this earnings season are PetMed Express (PETS), PerkinElmer (PKI) and Becton, Dickinson and Company (BDX). While PetMed sports a Zacks Rank #1 (Strong Buy), PerkinElmer and Becton, Dickinson carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.

PetMed reported third-quarter fiscal 2018 results. Adjusted earnings per share of 44 cents were up 88.3% from the prior-year quarter. Revenues rose 13.7% on a year-over-year basis to $60.1 million.

PerkinElmer reported fourth-quarter 2017 adjusted earnings per share of 97 cents. Adjusted revenues were approximately $641.6 million, up from $567 million in the year-ago quarter.

Becton, Dickinson reported first-quarter fiscal 2018 adjusted earnings per share of $2.48, up 3.9% at constant currency. Revenues totaled $3.08 billion, up 3.7% at constant currency.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

PetMed Express, Inc. (PETS): Free Stock Analysis Report

PerkinElmer, Inc. (PKI): Free Stock Analysis Report

Opko Health, Inc. (OPK): Free Stock Analysis Report

Becton, Dickinson and Company (BDX): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics

Earnings Stocks

Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More